Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2026)
Evommune (EVMN) reported Depreciation & Amortization (CF) of $349000.0 for Q1 2026, down 7.43% year-over-year from $377000.0 in Q1 2025, and up 7.06% quarter-over-quarter from $326000.0 in Q4 2025.
Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $349000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $349000.0, down 7.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY), and the FY2025 annual result was $1.4 million, up 7.93% from the prior year.
- Depreciation & Amortization (CF) climbed to $349000.0 in Q1 2026 per EVMN's latest filing, from $326000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $377000.0 in Q1 2025 and troughed at $326000.0 in Q4 2025.
- A 3-year average of $353000.0 and a median of $354500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) decreased 9.44% in 2025, then slipped 7.43% in 2026.
- A 3-year view of Depreciation & Amortization (CF) shows it stood at $360000.0 in 2024, then declined by 9.44% to $326000.0 in 2025, then rose by 7.06% to $349000.0 in 2026.
- Business Quant data shows EVMN's Depreciation & Amortization (CF) at $349000.0 in Q1 2026, $326000.0 in Q4 2025, and $377000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | 349,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 349,000.00 |
| Mar 31, 2026 | 349,000.00 |
| Dec 31, 2025 | 326,000.00 |
| Dec 31, 2025 | 326,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |